CA3065318A1 - The use of tegavivint to treat fibrotic disease - Google Patents

The use of tegavivint to treat fibrotic disease

Info

Publication number
CA3065318A1
CA3065318A1 CA3065318A CA3065318A CA3065318A1 CA 3065318 A1 CA3065318 A1 CA 3065318A1 CA 3065318 A CA3065318 A CA 3065318A CA 3065318 A CA3065318 A CA 3065318A CA 3065318 A1 CA3065318 A1 CA 3065318A1
Authority
CA
Canada
Prior art keywords
group
pulmonary fibrosis
alkyl
tegavivint
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3065318A
Other languages
English (en)
French (fr)
Inventor
Ruolan Han
Jon Northrup
Srinivas Rao Kasibhatla
Stephen Horrigan
Jeff Larson
Original Assignee
Iterion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterion Therapeutics Inc filed Critical Iterion Therapeutics Inc
Publication of CA3065318A1 publication Critical patent/CA3065318A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3065318A 2017-06-02 2018-06-01 The use of tegavivint to treat fibrotic disease Pending CA3065318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514541P 2017-06-02 2017-06-02
US62/514,541 2017-06-02
PCT/US2018/035646 WO2018223023A1 (en) 2017-06-02 2018-06-01 Methods for treatment of fibrotic diseases

Publications (1)

Publication Number Publication Date
CA3065318A1 true CA3065318A1 (en) 2018-12-06

Family

ID=64456126

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3065318A Pending CA3065318A1 (en) 2017-06-02 2018-06-01 The use of tegavivint to treat fibrotic disease

Country Status (6)

Country Link
US (3) US11298346B2 (https=)
EP (2) EP4656191A1 (https=)
JP (1) JP7159302B2 (https=)
CA (1) CA3065318A1 (https=)
ES (1) ES3055488T3 (https=)
WO (1) WO2018223023A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
WO2019099836A1 (en) * 2017-11-16 2019-05-23 Northwestern University Inhaled formulation of a molecular inhibitor of wnt/beta-catenin signaling for treating interstitial lung diseases
JP7551507B2 (ja) * 2018-06-01 2024-09-17 イテリオン・セラピューティクス・インコーポレイテッド テガビビントおよび関連化合物の製剤
EP4081209A4 (en) 2019-12-24 2024-04-24 The Regents of the University of California Compositions and methods for treating cancer and improving epithelial homeostasis
JP2023520867A (ja) * 2020-04-08 2023-05-22 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 損傷後の顔面拘縮に対処するための治療戦略
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11571388B2 (en) * 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
US11964054B2 (en) 2020-11-24 2024-04-23 Iterion Therapeutics, Inc. Formulations of tegavivint
CN119215047A (zh) * 2024-10-11 2024-12-31 浙江大学 一种芳香磺酰胺类化合物在制备防治肝损伤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2152258T (pt) * 2007-05-10 2016-08-18 Avalon Pharmaceuticals Derivados de fluoreno, antraceno, xanteno, dibenzosuberona e acridina e suas utilizações
EA030302B1 (ru) * 2008-11-21 2018-07-31 Форест Лэборетериз Холдингз Лимитед Антрахинондиоксимы и их применение
US8957107B2 (en) 2009-12-15 2015-02-17 The Hospital For Sick Children Method of treating scars and β-catenin-mediated disorders using Nefopam compounds
EP2773607B1 (en) 2011-11-06 2017-03-29 Beta Cat Pharmaceuticals LLC Treatment of diseases and disorders related to transducin beta-like protein 1 (tbl 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US20130123281A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
AU2014244506A1 (en) 2013-03-14 2015-09-17 Curegenix, Inc. Compounds for treatment of fibrosis diseases
TW201718495A (zh) 2015-07-28 2017-06-01 貝塔貓製藥股份有限公司 蒽-9, 10-二酮二肟化合物前驅藥及其用途
KR102651136B1 (ko) * 2016-04-12 2024-03-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 그 제조 방법
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
JP7551507B2 (ja) * 2018-06-01 2024-09-17 イテリオン・セラピューティクス・インコーポレイテッド テガビビントおよび関連化合物の製剤
US11571388B2 (en) * 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint

Also Published As

Publication number Publication date
EP3630101B1 (en) 2025-10-08
US11298346B2 (en) 2022-04-12
WO2018223023A1 (en) 2018-12-06
US20180344713A1 (en) 2018-12-06
EP3630101A4 (en) 2021-01-20
US20260102382A1 (en) 2026-04-16
EP4656191A1 (en) 2025-12-03
JP7159302B2 (ja) 2022-10-24
JP2020522567A (ja) 2020-07-30
EP3630101A1 (en) 2020-04-08
US20230012615A1 (en) 2023-01-19
ES3055488T3 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
US20260102382A1 (en) Methods for treatment of fibrotic diseases
EP1256576B1 (en) Fused imidazolium derivatives
SG10202110144TA (en) Compositions and methods for inhibiting arginase activity
KR20050042154A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물
JP2014196328A (ja) ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
EP3484862A1 (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
ES3057235T3 (en) Isoxazolidines as ripk1 inhibitors and use thereof
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms
JP2022512652A (ja) Ｐ２ｘ３拮抗薬での皮膚掻痒症の治療
CN101321523A (zh) Cb1拮抗剂在治疗精神分裂症的阴性症状中的用途
EP3573957B1 (en) Compositions and methods for blocking sodium channels
JP2018531959A (ja) 線維症疾患の治療及び／又は予防用インドリン誘導体
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
EP3833354B1 (en) Tissue transglutaminase modulators for medicinal use
US20130303538A1 (en) 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives
EP1648450A1 (de) Arzneimittel enthaltend derivate von aryl(oder heteroaryl)azolylcarbinolen
EP3424506B1 (en) Pharmaceutical composition for treating functional psychiatric disorders
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40063168A (en) Method for treating cough by using diaminopyrimidine compound
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
NZ765534B2 (en) P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
WO2012084873A1 (en) 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230525

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240814

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250321

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250422

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250422

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251030

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260211